EP
NVCT icon

Essential Partners’s Nuvectis Pharma NVCT Stock Holding History

Essential Partners’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$570 Hold
27
– – ﹤0.01% 2364
2026
Q2 		$497 Buy
27
+25
+1,250% +$280 ﹤0.01% 2475
2026
Q1 		$15 Buy
+2
New +$17 ﹤0.01% 2831

Other funds holding NVCT

Baldwin Wealth Partners
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return
J.M. Forbes & Co
J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's NVCT Position: Q3 2026 in Review

Essential Partners held its Nuvectis Pharma (NVCT) position steady in Q3 2026 at 27 shares worth $570. The position accounts for ﹤0.01% of the portfolio, ranked #2364.

Essential Partners first reported a position in NVCT in Q1 2026 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

  • Essential Partners held 27 shares of Nuvectis Pharma worth $570 as of Q3 2026.
  • Essential Partners left its Nuvectis Pharma share count unchanged in Q3 2026.
  • Nuvectis Pharma made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2364 holding.
  • Essential Partners first reported a position in Nuvectis Pharma in Q1 2026 and has held it in 3 quarters since.
  • 8 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.